Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Liver Diseases

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 96 articles:
HTML format



Single Articles


    May 2020
  1. PETRICK JL, Florio AA, Koshiol J, Pfeiffer RM, et al
    Prediagnostic Concentrations of Circulating Bile Acids and Hepatocellular Carcinoma Risk: REVEAL-HBV and HCV Studies.
    Int J Cancer. 2020 May 13. doi: 10.1002/ijc.33051.
    PubMed     Abstract available


    April 2020
  2. ANTWI SO, Petrick JL, Campbell PT, Norez DA, et al
    One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33007.
    PubMed     Abstract available


    March 2020
  3. TAK KY, Nam HC, Choi JY, Yoon SK, et al
    Effectiveness of Sorafenib Dose Modifications on Treatment Outcome of Hepatocellular Carcinoma: Analysis in Real-Life Settings.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32964.
    PubMed     Abstract available


  4. JUENGPANICH S, Topatana W, Lu C, Staiculescu D, et al
    Role of Cellular, Molecular, and Tumor Microenvironment in Hepatocellular Carcinoma: Possible Targets and Future Directions in the Regorafenib Era.
    Int J Cancer. 2020 Mar 12. doi: 10.1002/ijc.32970.
    PubMed     Abstract available


  5. TRAN KT, McMenamin UC, Coleman HG, Cardwell CR, et al
    Statin use and risk of liver cancer: Evidence from two population-based studies.
    Int J Cancer. 2020;146:1250-1260.
    PubMed     Abstract available


  6. STRIJKER M, Soer EC, de Pastena M, Creemers A, et al
    Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Int J Cancer. 2020;146:1445-1456.
    PubMed     Abstract available


  7. KHARE T, Khare S, Angdisen JJ, Zhang Q, et al
    Defects in long chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
    Int J Cancer. 2020 Mar 1. doi: 10.1002/ijc.32943.
    PubMed     Abstract available


    February 2020
  8. RUAN Q, Wang H, Burke LJ, Bridle KR, et al
    Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32899.
    PubMed     Abstract available


    January 2020
  9. HAGGSTROM C, Jonsson H, Bjorge T, Nagel G, et al
    Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals.
    Int J Cancer. 2020;146:58-67.
    PubMed     Abstract available


    December 2019
  10. ABRAHAMSSON H, Jensen BV, Berven LL, Nielsen DL, et al
    Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation; 8-12 years of follow-up.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32847.
    PubMed     Abstract available


    November 2019
  11. IIOKA H, Saito K, Sakaguchi M, Tachibana T, et al
    Crumbs3 is a critical factor that regulates invasion and metastasis of colon adenocarcinoma via the specific interaction with FGFR1.
    Int J Cancer. 2019;145:2740-2753.
    PubMed     Abstract available


  12. MELLO T, Materozzi M, Zanieri F, Simeone I, et al
    Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32787.
    PubMed     Abstract available


  13. ENGEL LS, Zabor EC, Satagopan J, Widell A, et al
    Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts.
    Int J Cancer. 2019;145:2360-2371.
    PubMed     Abstract available


    October 2019
  14. PETRICK JL, Florio AA, Znaor A, Ruggieri D, et al
    International trends in hepatocellular carcinoma incidence, 1978-2012.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32723.
    PubMed     Abstract available


  15. LAI SW
    Statins use and risk of liver cancer.
    Int J Cancer. 2019;145:2008.
    PubMed    


  16. TRAN KT, Cardwell CR, Thrift AP
    Authors' reply to: Statin use and risk of liver cancer.
    Int J Cancer. 2019;145:2009.
    PubMed    


    September 2019
  17. PANG Y, Kartsonaki C, Guo Y, Chen Y, et al
    Central adiposity in relation to risk of liver cancer in Chinese adults: A prospective study of 0.5 million people.
    Int J Cancer. 2019;145:1245-1253.
    PubMed     Abstract available


    August 2019
  18. YU J, Ding WB, Wang MC, Guo XG, et al
    Plasma Circular RNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma: A Large-Scale, Multicenter Study.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32647.
    PubMed     Abstract available


    July 2019
  19. HAN J, Han ML, Xing H, Li ZL, et al
    Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Int J Cancer. 2019 Jul 30. doi: 10.1002/ijc.32599.
    PubMed     Abstract available


  20. HU B, Li H, Guo W, Sun YF, et al
    Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
    Int J Cancer. 2019 Jul 16. doi: 10.1002/ijc.32564.
    PubMed     Abstract available


  21. ZHOU Y, Li Y, Xu S, Lu J, et al
    Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32560.
    PubMed     Abstract available


    June 2019
  22. CASTVEN D, Becker D, Czauderna C, Wilhelm D, et al
    Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
    Int J Cancer. 2019;144:2782-2794.
    PubMed     Abstract available


    May 2019
  23. YANG W, Sui J, Ma Y, Simon TG, et al
    A prospective study of dairy product intake and the risk of hepatocellular carcinoma in U.S. men and women.
    Int J Cancer. 2019 May 22. doi: 10.1002/ijc.32423.
    PubMed     Abstract available


  24. YANG Y, Chen Q, Piao HY, Wang B, et al
    HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma.
    Int J Cancer. 2019 May 15. doi: 10.1002/ijc.32409.
    PubMed     Abstract available


  25. JIANG T, Chu Q, Wang H, Zhou F, et al
    EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Int J Cancer. 2019;144:2605-2612.
    PubMed     Abstract available


  26. YIN S, Qiu Y, Jin C, Wang R, et al
    7-deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma.
    Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32395.
    PubMed     Abstract available


  27. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    PubMed     Abstract available


    April 2019
  28. IIDA N, Mizukoshi E, Yamashita T, Terashima T, et al
    Overuse of anti-anaerobic drug is associated with poor post-chemotherapy prognosis of patients with hepatocellular carcinoma.
    Int J Cancer. 2019 Apr 13. doi: 10.1002/ijc.32339.
    PubMed     Abstract available


  29. YANG P, Huang X, Lai C, Li L, et al
    SET domain containing 1B gene (SETD1B) is mutated in primary hepatic neuroendocrine tumors.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32334.
    PubMed     Abstract available


  30. GE Z, Feng Y, Sheh A, Muthupalani S, et al
    Mutagenicity of Helicobacter hepaticus infection in the lower bowel mucosa of 129/SvEv Rag2(-/-) Il10(-/-) gpt delta mice is influenced by sex.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32332.
    PubMed     Abstract available


    March 2019
  31. TAN HW, Leung CO, Chan KK, Ho DW, et al
    Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.
    Int J Cancer. 2019 Mar 4. doi: 10.1002/ijc.32248.
    PubMed     Abstract available


    February 2019
  32. VAN BEEK AA, Zhou G, Doukas M, Boor PPC, et al
    GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32181.
    PubMed     Abstract available


    January 2019
  33. WANG Y, Tan PY, Handoko YA, Sekar K, et al
    NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32134.
    PubMed     Abstract available


  34. SANCHEZ-MEJIAS A, Kwon J, Chew XH, Siemens A, et al
    A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.
    Int J Cancer. 2019;144:311-321.
    PubMed     Abstract available


  35. DU Y, Song W, Chen J, Chen H, et al
    The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32121.
    PubMed     Abstract available


  36. DEVAUD C, Tilkin-Mariame AF, Vignolle-Vidoni A, Souleres P, et al
    FAK alternative splice mRNA variants expression pattern in colorectal cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32120.
    PubMed     Abstract available


    November 2018
  37. AUGELLO G, Emma MR, Cusimano A, Azzolina A, et al
    Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.31963.
    PubMed     Abstract available


  38. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    PubMed     Abstract available


  39. FANG AP, Chen PY, Wang XY, Liu ZY, et al
    Serum Copper and Zinc levels at Diagnosis and Hepatocellular Carcinoma Survival in the Guangdong Liver Cancer Cohort.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31991.
    PubMed     Abstract available


  40. SHENG Y, Wei J, Zhang Y, Gao X, et al
    Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31979.
    PubMed     Abstract available


  41. CHEN VC, Chan HL, Hsu TC, Lu ML, et al
    New use for old drugs: the protective effect of atypical antipsychotics on hepatocellular carcinoma.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31980.
    PubMed     Abstract available


    October 2018
  42. LEE YR, Kim G, Tak WY, Jang SY, et al
    Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
    Int J Cancer. 2018 Oct 19. doi: 10.1002/ijc.31931.
    PubMed     Abstract available


  43. MA X, Tan YT, Yang Y, Gao J, et al
    Pre-diagnostic urinary 15-F2t -isoprostane level and liver cancer risk: Results from the Shanghai Women's and Men's Health Studies.
    Int J Cancer. 2018;143:1896-1903.
    PubMed     Abstract available


  44. ABDUL-WAHID A, Cydzik M, Fischer NW, Prodeus A, et al
    Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
    Int J Cancer. 2018;143:1963-1977.
    PubMed     Abstract available


  45. YANG J, Trepo E, Nahon P, Cao Q, et al
    PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31910.
    PubMed     Abstract available


    September 2018
  46. LEE JH
    Analysis of The Cancer Genome Atlas data to determine the correlation between PROX1 and TERT in hepatocellular carcinoma.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31888.
    PubMed    


  47. CHEN G, Cai Z, Li Z, Dong X, et al
    Clonal evolution in long-term follow-up patients with hepatocellular carcinoma.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31844.
    PubMed     Abstract available


    August 2018
  48. MCGEE EE, Castro FA, Engels EA, Freedman ND, et al
    Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31835.
    PubMed     Abstract available


  49. MARTINEZ-CARDONA C, Lozano-Ruiz B, Bachiller V, Peiro G, et al
    AIM2 deficiency reduces the development of hepatocellular carcinoma in mice.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31827.
    PubMed     Abstract available


  50. WAN J, Liu H, Yang L, Ma L, et al
    JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31816.
    PubMed     Abstract available


  51. BAO C, Pedersen NL, Yang R, Marseglia A, et al
    Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2018;143:793-800.
    PubMed     Abstract available


    July 2018
  52. KIM YJ, Yoo JE, Jeon Y, Uk Chong J, et al
    Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31731.
    PubMed     Abstract available


    June 2018
  53. BOYSEN AK, Spindler KL, Hoyer M, Mortensen FV, et al
    Metastasis directed therapy for liver and lung metastases from colorectal cancer - a population based study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31626.
    PubMed     Abstract available


  54. ARAI J, Goto K, Tanoue Y, Ito S, et al
    Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Int J Cancer. 2018 Jun 6. doi: 10.1002/ijc.31615.
    PubMed     Abstract available


    May 2018
  55. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    PubMed     Abstract available


    April 2018
  56. LIU Y, De Keyzer F, Wang Y, Wang F, et al
    The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31567.
    PubMed     Abstract available


  57. CHEN CJ, Yang YH, Lin MH, Lee CP, et al
    Herbal Medicine Containing Aristolochic Acid and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31544.
    PubMed     Abstract available


  58. KAJI K, Nishimura N, Seki K, Sato S, et al
    Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Int J Cancer. 2018;142:1712-1722.
    PubMed     Abstract available


    March 2018
  59. LI X, Guo X, Li D, Du X, et al
    Multi-regional Sequencing Reveals Intratumor Heterogeneity and Positive Selection of Somatic mtDNA Mutations in Hepatocellular Carcinoma and Colorectal Cancer.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31395.
    PubMed     Abstract available


  60. JAQUET A, Tchounga B, Tanon A, Bagny A, et al
    Etiology of hepatocellular carcinoma in West Africa, a case-control study.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31393.
    PubMed     Abstract available


    February 2018
  61. MARQUEZ J, Fernandez-Pineiro I, Arauzo-Bravo MJ, Poschmann G, et al
    Targeting liver sinusoidal endothelial cells with miR-20a-loaded nanoparticles reduces murine colon cancer metastasis to the liver.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31343.
    PubMed     Abstract available


  62. PULTE D, Weberpals J, Schroder CC, Emrich K, et al
    Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21(st) century.
    Int J Cancer. 2018 Feb 26. doi: 10.1002/ijc.31322.
    PubMed     Abstract available


  63. BONNESEN TG, Winther JF, Andersen KK, Asdahl PH, et al
    Liver diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): A population-based cohort study of 32,839 one-year survivors.
    Int J Cancer. 2018;142:702-708.
    PubMed     Abstract available


    December 2017
  64. CHANG CJ, Yang YH, Chiu CJ, Lu LC, et al
    Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31216.
    PubMed     Abstract available


    November 2017
  65. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Abstract available


    October 2017
  66. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114.
    PubMed     Abstract available


  67. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Abstract available


    September 2017
  68. JIANG W, Shen Y, Ding Y, Ye C, et al
    A naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31054.
    PubMed     Abstract available


  69. WANG W, Xiao X, Chen X, Huo Y, et al
    Tumor-suppressive miR-145 co-repressed by TCF4-beta-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31056.
    PubMed     Abstract available


  70. SONG IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, et al
    The Contribution of Toll-Like Receptor Signaling to the Development of Liver Fibrosis and Cancer in Hepatocyte-Specific TAK1-Deleted Mice.
    Int J Cancer. 2017 Sep 5. doi: 10.1002/ijc.31029.
    PubMed     Abstract available


    August 2017
  71. LI S, Dai W, Mo W, Li J, et al
    By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Int J Cancer. 2017 Aug 31. doi: 10.1002/ijc.31022.
    PubMed     Abstract available


  72. DENG H, Eckel SP, Liu L, Lurmann FW, et al
    Particulate matter air pollution and liver cancer survival.
    Int J Cancer. 2017;141:744-749.
    PubMed     Abstract available


    July 2017
  73. YANG B, Petrick JL, Kelly SP, Graubard BI, et al
    Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.
    Int J Cancer. 2017;141:271-278.
    PubMed     Abstract available


    June 2017
  74. LIN B, Zhu M, Wang W, Li W, et al
    Structural basis for alpha fetoprotein-mediated inhibition of caspase-3 activity in hepatocellular carcinoma cells.
    Int J Cancer. 2017 Jun 27. doi: 10.1002/ijc.30850.
    PubMed     Abstract available


  75. ZHANG Q, Yuan XF, Lu Y, Li ZZ, et al
    Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
    Int J Cancer. 2017 Jun 23. doi: 10.1002/ijc.30846.
    PubMed     Abstract available


  76. SHI H, Fang W, Liu M, Fu D, et al
    Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.
    Int J Cancer. 2017 Jun 12. doi: 10.1002/ijc.30831.
    PubMed     Abstract available


  77. WANG K, Nie X, Rong Z, Fan T, et al
    B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
    Int J Cancer. 2017 Jun 5. doi: 10.1002/ijc.30823.
    PubMed     Abstract available


  78. NDERITU P, Bosco C, Garmo H, Holmberg L, et al
    The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30818.
    PubMed     Abstract available


  79. MTEYREK A, Filipski E, Guettier C, Oklejewicz M, et al
    Critical cholangiocarcinogenesis control by cryptochrome clock genes.
    Int J Cancer. 2017;140:2473-2483.
    PubMed     Abstract available


    May 2017
  80. SHOJI H, Yoshio S, Mano Y, Doi H, et al
    Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 27. doi: 10.1002/ijc.30804.
    PubMed     Abstract available


  81. CAI ZX, Chen G, Zeng YY, Dong XQ, et al
    Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 22. doi: 10.1002/ijc.30798.
    PubMed     Abstract available


  82. CHU YJ, Yang HI, Wu HC, Liu J, et al
    Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30782.
    PubMed     Abstract available


  83. LEE TY, Wu JC, Yu SH, Lin JT, et al
    The occurrence of hepatocellular carcinoma in different risk stratifications of clinically non-cirrhotic non-alcoholic fatty liver disease.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30784.
    PubMed     Abstract available


    April 2017
  84. ZHANG R, Real CI, Liu C, Baba HA, et al
    Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.
    Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30742.
    PubMed     Abstract available


  85. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    PubMed     Abstract available


  86. KE Y, Bao T, Zhou Q, Wang Y, et al
    Discs large homolog 5 decreases formation and function of invadopodia in human hepatocellular carcinoma via Girdin and Tks5: Dlg5 regulates HCC invadopodia.
    Int J Cancer. 2017 Apr 8. doi: 10.1002/ijc.30730.
    PubMed     Abstract available


    March 2017
  87. ZHU M, Li W, Lu Y, Dong X, et al
    HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
    Int J Cancer. 2017;140:1346-1355.
    PubMed     Abstract available


  88. MA X, Yang Y, Li HL, Zheng W, et al
    Dietary trace element intake and liver cancer risk: Results from two population-based cohorts in China.
    Int J Cancer. 2017;140:1050-1059.
    PubMed     Abstract available


    February 2017
  89. ZHANG D, Zhao L, Shen Q, Lv Q, et al
    Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30656.
    PubMed     Abstract available


  90. XU J, Lin H, Li G, Sun Y, et al
    Sorafenib with ASC-J9(R) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.
    Int J Cancer. 2017;140:705-717.
    PubMed     Abstract available


    January 2017
  91. WANG W, Bai W, Wang E, Zhao Y, et al
    mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Int J Cancer. 2017;140:390-399.
    PubMed     Abstract available


    August 2016
  92. ZHAO Y, Li H, Bai W, Liu J, et al
    Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Int J Cancer. 2016;139:928-37.
    PubMed     Abstract available


  93. HASHIMOTO M, Kobayashi T, Tashiro H, Arihiro K, et al
    h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Int J Cancer. 2016;139:812-23.
    PubMed     Abstract available


  94. KURAHARA H, Bohl C, Natsugoe S, Nishizono Y, et al
    Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.
    Int J Cancer. 2016;139:628-38.
    PubMed     Abstract available


    July 2016
  95. JARY M, Lecomte T, Bouche O, Kim S, et al
    Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: A simple biological score.
    Int J Cancer. 2016 Jul 29. doi: 10.1002/ijc.30367.
    PubMed     Abstract available


    March 2016
  96. LOES IM, Immervoll H, Sorbye H, Angelsen JH, et al
    Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: